ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.
The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.
ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.
The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.
Covalent screening has become a powerful strategy in modern small-molecule drug discovery, enabling researchers to tackle targets that are often difficult to address using traditional approaches. Once viewed as high risk, covalent strategies are now widely recognized for their ability to deliver potent, selective, and long-lasting therapeutics.
Unlike conventional screening methods, covalent approaches rely on more than transient binding interactions. They require a carefully tuned balance between reversible target recognition and covalent bond…
As part of our mission to tackle some of the toughest targets in drug discovery, we’ve recently expanded our early discovery capabilities to include covalent compound library screening. Our early discovery site in Leiden is already well-known for its success in first-in-class and hard-to-drug targets, and this addition reflects a growing shift in the field: covalent approaches are no longer a last resort, they are becoming a smart, mechanism-led starting point for small molecule discovery. To understand what makes covalent screening so powerful…